Tags: University of Melbourne, Australia, Healthcare & Lifesciences
Researchers found a strategy for a live, safe rabies vaccine, overcoming inactivated vaccines' limits. By mutating a protein in the lyssavirus, they've developed a vaccine strain that's safe and effective in vivo. This innovation meets a critical need, with rabies causing nearly 59,000 deaths yearly. Live vaccines, unlike inactivated ones, are easier to produce and more immunogenic. This breakthrough could lead to a 'best in class' rabies vaccine.
IP Type or Form Factor: Patent Pending; Platform
TRL: Not specified
Industry or Tech Area: Vaccines; Biotechnology
![Attenuation Strategies for Live Rabies Vaccine](https://substackcdn.com/image/fetch/w_474,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd2b8526d-a932-40fd-b5af-aa649319f1b1_1024x1024.jpeg)
![Attenuation Strategies for Live Rabies Vaccine](https://substackcdn.com/image/fetch/w_474,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9a40f4a0-5d5f-40a2-983e-86d3004ef60e_728x504.png)
![Attenuation Strategies for Live Rabies Vaccine](https://substackcdn.com/image/fetch/w_474,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F197ace4d-ce92-47de-8e2d-cd5b21786262_744x517.png)